NCT02994147View on ClinicalTrials.gov

A Proof-of-Concept Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Hemophilic Arthropathy

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

March 21, 2017

Primary Completion Date

April 18, 2019

Study Completion Date

October 2, 2019

Conditions
Hemophilic Arthropathy
Interventions
DRUG

Placebo

Placebo-only control study medication is the same formulation as active treatment without active ingredient

DRUG

AC-201CR

The investigational product is formulated as controlled-release (CR) tablets

Trial Locations (1)

Unknown

Tri-Service General Hospital, Taipei

All Listed Sponsors
lead

TWi Biotechnology, Inc.

INDUSTRY

NCT02994147 - A Proof-of-Concept Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Hemophilic Arthropathy | Biotech Hunter | Biotech Hunter